Kintor Pharmaceutical Ltd (HK:9939)
:9939
Want to see HK:9939 full AI Analyst Report?
9939 Stock Chart & Stats
HK$1.92
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.92
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.40 - HK$4.70
Previous CloseN/A
Volume545.00K
Average Volume (3M)4.99M
Market Cap
HK$1.31B
Enterprise ValueHK$983.40M
Total Cash (Recent Filing)HK$34.78M
Total Debt (Recent Filing)HK$86.64M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding498,660,100
10 Day Avg. Volume2,605,850
30 Day Avg. Volume4,990,601
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp revenue rebound in 2025 and narrowing losses indicate improving top-line momentum and stronger cash inflows from operations or milestones. If sustained, this reduces near-term funding pressure, extends runway for R&D programs, and lowers reliance on dilutive financing over the medium term.
High Reported Revenue GrowthA reported RevenueGrowth figure of ~557% reflects significant year-over-year top-line acceleration, suggesting the business is exiting a trough and capturing demand or milestone revenue. Durable high growth, if maintained, supports scale benefits and validates commercial or partnership traction for pipeline assets.
Moderate Financial LeverageDebt-to-equity near 0.45–0.55 is moderate for a development-stage biotech, leaving financial flexibility versus highly levered peers. This capital structure limits interest burden, helps absorb R&D volatility, and provides management scope to fund programs before resorting to distressed or highly dilutive financing.
Bears Say
Negative Gross Profit And Persistent LossesNegative gross profit through 2024–2025 indicates that core activities are not yet generating positive unit economics. Structural gross losses undermine margin sustainability and mean scaling revenue alone may not translate to profitability without lowered COGS, higher pricing, or significant operational changes.
Consistent Cash BurnConsistently negative operating and free cash flow, with cash burn accelerating in 2024–2025, signals reliance on external capital. Chronic cash shortfalls force recurrent fundraising, increase dilution risk, constrain investment choices, and elevate execution risk if financing conditions tighten.
Eroding Balance SheetMaterial declines in assets and shareholders' equity reflect cumulative operating losses and value erosion. A weakening balance sheet reduces borrowing capacity, limits strategic optionality, and heightens solvency risk if losses persist or if the company cannot secure non-dilutive funding.
Kintor Pharmaceutical Ltd News
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
Kintor Pharmaceutical Ltd lowest stock price was HK$1.40 and its highest was HK$4.70 in the past 12 months.
What is Kintor Pharmaceutical Ltd’s market cap?
Kintor Pharmaceutical Ltd’s market cap is HK$1.31B.
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
Kintor Pharmaceutical Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 87 days.
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Kintor Pharmaceutical Ltd released its earnings results on Mar 30, 2026. The company reported -HK$0.277 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.277.
Is Kintor Pharmaceutical Ltd overvalued?
According to Wall Street analysts Kintor Pharmaceutical Ltd’s price is currently Overvalued.
Does Kintor Pharmaceutical Ltd pay dividends?
Kintor Pharmaceutical Ltd does not currently pay dividends.
What is Kintor Pharmaceutical Ltd’s EPS estimate?
Kintor Pharmaceutical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kintor Pharmaceutical Ltd have?
Kintor Pharmaceutical Ltd has 498,660,100 shares outstanding.
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Kintor Pharmaceutical Ltd reported an EPS of -HK$0.277 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.216%.
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:9939
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kintor Pharmaceutical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.57%
12-Months-Change
Fundamentals
Return on Equity
-98.56%
Trailing 12-Months
Asset Growth
-30.76%
Trailing 12-Months
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
3D Medicines, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---